Lupin launches Alzheimer’s drug in the US

Pharma major Lupin said it has launched the generic version of Allergan’s Alzheimer’s drug Namenda XR in the US.

The medicine has annual sales of approximately USD 936 million in the US, making it almost a billion-dollar drug.

The launch was done in dosages of 7mg, 14mg, 21mg and 28mg of Memantine Hydrochloride.

The drug is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type.

Lupin is an Indian drugmaker that focuses on Cardiovascular, Diabetology, Asthma, Paediatric, CNS, GI, Anti-Infective and NSAID space.

It is also the world’s No.1 in TB medicines.

For the financial year ended March, 2017, Lupin’s consolidated sales and stood at Rs 171,198 million